Related references
Note: Only part of the references are listed.Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
Chiara Conti et al.
CANCER RESEARCH (2010)
The molecular signature of oncofusion proteins in acute myeloid leukemia
Joost H. A. Martens et al.
FEBS LETTERS (2010)
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
Andelko Hrzenjak et al.
MOLECULAR CANCER (2010)
Histone deacetylase inhibitors and genomic instability
Gregory Eot-Houllier et al.
CANCER LETTERS (2009)
A phase 2 study of vorinostat in acute myeloid leukemia
Eric W. Schaefer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
Clara Campas-Moya
DRUGS OF TODAY (2009)
Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling
Xin Yi et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Jennifer S. Carew et al.
CANCER LETTERS (2008)
OSU-HDAC42, a Histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model
Aaron M. Sargeant et al.
CANCER RESEARCH (2008)
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
Kei-ichi Ozaki et al.
CANCER SCIENCE (2008)
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control
Srividya Bhaskara et al.
MOLECULAR CELL (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis
O. H. Kraemer et al.
ONCOGENE (2008)
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Shanthi Adimoolam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Global chromatin compaction limits the strength of the DNA damage response
Matilde Murga et al.
JOURNAL OF CELL BIOLOGY (2007)
Attenuated DNA damage repair by trichostatin a through BRCA1 suppression
Yin Zhang et al.
RADIATION RESEARCH (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
The molecular biology of mammalian SIRT proteins - SIRT2 in cell cycle regulation
Toshiaki Inoue et al.
CELL CYCLE (2007)
PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway
Dong-Oh Moon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
Weisheng Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
Terry J. Gaymes et al.
MOLECULAR CANCER RESEARCH (2006)
Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells
A Martirosyan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The comet assay: a method to measure DNA damage in individual cells
Peggy L. Olive et al.
NATURE PROTOCOLS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Prospects: Histone deacetylase inhibitors
M Dokmanovic et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
A Munshi et al.
CLINICAL CANCER RESEARCH (2005)
Localized histone acetylation and deacetylation triggered by the homologous recombination pathway of double-strand DNA repair
BA Tamburini et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Histone deacetylase inhibitors and malignant melanoma
GM Boyle et al.
PIGMENT CELL RESEARCH (2005)
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species
M Rahmani et al.
CANCER RESEARCH (2005)
Saccharomyces cerevisiae Sin3p facilitates DNA double-strand break repair
A Jazayeri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
DNA double-strand breaks and γ-H2AX signaling in the testis
G Hamer et al.
BIOLOGY OF REPRODUCTION (2003)
Dynamics and diversions in base excision DNA repair of oxidized abasic lesions
B Demple et al.
ONCOGENE (2002)
Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid-resistant APL cells
S Côté et al.
BLOOD (2002)
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells
AA Ruefli et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)
HM Amin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Transcription therapy for cancer
PP Pandolfi
ONCOGENE (2001)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
